Article

Protection against omicron severe disease 0-7 months after BNT162b2 booster

2022-05-05

Abstract excerpt

Following a rise in cases due to the delta variant and evidence of waning immunity after 2 doses of the BNT162b2 vaccine, Israel began administering a third BNT162b2 dose (booster) in July 2021. Recent studies showed that the 3rd dose provides a much lower protection against infection with the omicron variant compared to the delta variant and that this protection wanes quickly. In this study, we used data from Isr...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a7cfdef1-059c-5205-8d31-cad9e691ab77
DOI: 10.1101/2022.05.04.22274647

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Protection against omicron severe disease 0-7 months after BNT162b2 boosterDOI 10.1101/2022.05.04.22274647Read

BNT162b2 vaccine booster dose protection: A nationwide study from IsraelSemantic proximity Read

Relative Effectiveness of Four Doses Compared to Three Dose of the BNT162b2 Vaccine in IsraelSemantic proximity Read

Immune Response and Clinical Outcomes of BNT162b2 and mRNA1273 Fourth Dose COVID-19 Vaccines; Three Months Follow-upSemantic proximity Read

Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concernSemantic proximity Read

Antibody and T cell responses against wild-type and Omicron SARS-CoV-2 after the third dose of BNT162b2 in healthy adolescentsSemantic proximity Read

Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron VariantSemantic proximity Read

Effectiveness of the BNT162b vaccine fourth dose in reducing SARS-CoV-2 infection among healthcare workers in Israel, a multi-center cohort studySemantic proximity Read

Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in BrazilSemantic proximity Read

Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in QatarSemantic proximity Read

Short Term Reduction in the Odds of Testing Positive for SARS-CoV-2; a Comparison Between Two Doses and Three doses of the BNT162b2 VaccineSemantic proximity Read

The Effectiveness of the First Dose of BNT162b2 Vaccine in Reducing SARS-CoV-2 Infection: Real-World EvidenceSemantic proximity Read

Impact of Vaccination, Prior Infection, and Therapy on Delta and Omicron VariantsSemantic proximity Read